Tirzepatide was associated with better glycemic control and weight loss outcomes than semaglutide and insulin among patients with T2D.

adult participants with obesity but without type 2 diabetes were randomly assigned in a 1:1 ratio to receive the maximum tolerated dose of tirzepatide (10 mg or 15 mg) or the maximum tolerated ...

Participants were randomly assigned to receive once-weekly subcutaneous injections of tirzepatide (10 mg or 15 mg) or semaglutide (1.7 mg or 2.4 mg) for 72 weeks. Dosing began at 2.5 mg for ...

The SURPASS 1 through 5 studies were phase 3 clinical trials in which researchers compared the efficacy of 5, 10, or 15 mg tirzepatide with placebo, 1 mg semaglutide, insulin degludec, or insulin ...

In a 72-week clinical trial, tirzepatide (Zepbound) led to significantly greater weight loss than semaglutide (Wegovy), with ...

Participants were randomized 1:1 to receive either the maximum tolerated dose of tirzepatide (10 or 15 mg; n = 374) or semaglutide (1.7 or 2.4 mg; n = 376) once weekly for 72 weeks. Most ...

Mounjaro (tirzepatide) will be available in the market from the end of May 2025BANGKOK, THAILAND - Media OutReach Newswire - 27 May 2025 - Zu ...

Participants received a maximum tolerated shot of tirzepatide (10 mg or 15 mg) or the maximum tolerated shot of semaglutide (1.7 mg or 2.4 mg) once weekly. In the tirzepatide group, 89.3% received ...

Despite promising adherence and persistence data, tirzepatide dose escalation was slower in the real-world than clinical trials in patients with obesity without T2D. Tirzepatide dose escalation is ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

Tirzepatide, the newest weight loss drug in India, is transforming the wellness market with its hormone-mimicking effects.

The trial randomized 751 participants across the US and Puerto Rico in a 1:1 ratio to receive maximum tolerated dose of tirzepatide (10 mg or 15 mg) or semaglutide (1.7 mg or 2.4 mg). With tirzepatide ...